Abstract
DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and specificity. In the process of binding to target proteins, the reason why DARPins have high affinity to target proteins as well as the correlation among sequences, structures, dynamical behaviors and binding to target proteins are still unknown. This paper studied DARPins using the AMBER package with ff03 force field for molecular dynamics simulations, providing a theoretical basis for the research on a new type of protein drug. This shows that the DARPins have more dynamical behaviors regularity after binding to target proteins compared with non-binding DARPins, but the binding to target proteins does not always stabilize the structures of DARPins, and the changes in the regions of β-turn and loop are the most obvious. The changes in hydrogen bonds and hydrophobic interactions have close relationship with the changes in the stability and cross correlation of DARPins.
Keywords: Molecular dynamics simulation DARPins protein drug, dynamical cross correlation stability, binding proteins, monoclonal antibodies, alternatives, AMBER package, theoretical basis, target proteins, β-turn, loop
Current Pharmaceutical Design
Title:Exploring the Relationship between Sequences, Structures, Dynamical Behaviors and Functions of New Type Protein Drugs: DARPins
Volume: 19 Issue: 12
Author(s): Xue Wu, Yue Shi, Pengyu Ren, Deping Wang and Guohui Li
Affiliation:
Keywords: Molecular dynamics simulation DARPins protein drug, dynamical cross correlation stability, binding proteins, monoclonal antibodies, alternatives, AMBER package, theoretical basis, target proteins, β-turn, loop
Abstract: DARPins (designed ankyrin repeat proteins), new kinds of binding proteins, have the potential to overcome the defects of monoclonal antibodies, and hence may become the alternatives to antibodies and generate a novel therapeutic approach. DARPins can be selected to bind any given target proteins with high affinity and specificity. In the process of binding to target proteins, the reason why DARPins have high affinity to target proteins as well as the correlation among sequences, structures, dynamical behaviors and binding to target proteins are still unknown. This paper studied DARPins using the AMBER package with ff03 force field for molecular dynamics simulations, providing a theoretical basis for the research on a new type of protein drug. This shows that the DARPins have more dynamical behaviors regularity after binding to target proteins compared with non-binding DARPins, but the binding to target proteins does not always stabilize the structures of DARPins, and the changes in the regions of β-turn and loop are the most obvious. The changes in hydrogen bonds and hydrophobic interactions have close relationship with the changes in the stability and cross correlation of DARPins.
Export Options
About this article
Cite this article as:
Wu Xue, Shi Yue, Ren Pengyu, Wang Deping and Li Guohui, Exploring the Relationship between Sequences, Structures, Dynamical Behaviors and Functions of New Type Protein Drugs: DARPins, Current Pharmaceutical Design 2013; 19 (12) . https://dx.doi.org/10.2174/1381612811319120017
DOI https://dx.doi.org/10.2174/1381612811319120017 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Letters in Drug Design & Discovery Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology Effective Anticancer Drug and Food Choices Based on Polyamine Levels in Cancer Tissues
Current Drug Therapy Nanocrystal Based Drug Delivery System: Conventional and Current Scenario
Recent Patents on Nanotechnology Ghrelin: New Insight to Mechanisms and Treatment of Postoperative Gastric Ileus
Current Pharmaceutical Design P-Glycoprotein Is Not a Key Target for the Chemosensitizing Effect of 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol in HepG2 Cells Exposed to Doxorubicin
Drug Metabolism Letters Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion
Current Medicinal Chemistry Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Targeted Tumor Therapies at a Glance
Current Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information
Current Pharmaceutical Design Editorial (Thematic Issue: From Phytochemistry to Medicinal Chemistry: Isolation, Semisynthesis, Evaluation and Computational Studies)
Current Topics in Medicinal Chemistry Application of Mesenchymal Stem Cells in the Targeted Gene Therapy for Gastric Cancer
Current Stem Cell Research & Therapy Exploring Structure-Activity Relationships of Tricyclic Farnesyltransferase Inhibitors Using ECLiPS® Libraries
Combinatorial Chemistry & High Throughput Screening PET and PET/CT: Conceptions, Misconceptions, and a Potential New Paradigm for Enhanced Metabolic Imaging
Current Medical Imaging Drug-Metabolizing Enzymes Mechanisms and Functions
Current Drug Metabolism Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets ent-Kaurane Diterpenoids from Croton tonkinensis Induce Apoptosis in Colorectal Cancer Cells through the Phosphorylation of JNK Mediated by Reactive Oxygen Species and Dual-Specificity JNK Kinase MKK4
Anti-Cancer Agents in Medicinal Chemistry Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets